Archives
-
Auranofin in HCC: A Redox Assay Strategy
2026-09-14
Auranofin offers a practical way to interrogate thioredoxin reductase dependence alongside the FOXO3–YAP metabolic program in hepatocellular carcinoma. This article translates recent HCC findings into a decision framework for redox, viability, apoptosis, and radiosensitization assays while distinguishing evidence from hypothesis.
-
Recombinant Human FGF-19: Assay Design Guide
2026-09-14
This scenario-based guide explains how Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized), SKU P1050, can support reproducible FGFR4 binding, proliferation, viability, and exploratory metabolic-signaling studies. It combines product specifications with practical controls and clear limits when extending FGF-19 experiments into renal inflammatory models.
-
Synthetic Lethality in Glioblastoma: Mcl-1 and BCL-XL
2026-09-13
The reference study identifies a super-enhancer controlling Mcl-1 expression in glioblastoma and shows that its epigenetic disruption can cooperate with BCL-2/BCL-XL inhibition to overcome apoptotic resistance. Across cellular and patient-derived xenograft models, the combination produced mitochondrial dysfunction, caspase activation, and reduced tumor growth, supporting a mechanistically defined strategy for preclinical GBM research.
-
JSH-23: A Mechanistic Guide to NF-κB Assays
2026-09-12
JSH-23 is an NF-κB inhibitor that can separate p65-dependent transcription from upstream IκB degradation and downstream inflammasome maturation. This guide translates PRV infection findings into practical assay decisions for inflammation research and disease modeling.
-
DAPI Nuclear Stain Solution: Practical Protocol
2026-09-11
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution is a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint assessment of membrane-compromised cells. It is best suited to fixed, dead, or apoptotic samples analyzed by fluorescence microscopy or flow cytometry, rather than routine imaging of intact live cells.
-
Machine-Learning LNPs for Microglial Repolarization
2026-09-11
Rafiei, Shojaei, and Chau combined a 216-formulation lipid nanoparticle screen with supervised machine learning to predict mRNA transfection and microglial phenotypic responses. Their best formulation, HA-LNP2, delivered IL10 mRNA and reduced inflammatory features in activated murine and human iPSC-derived microglia, supporting a cell-state-aware approach to neuroinflammatory drug delivery.
-
Itraconazole for Candida Biofilm Workflows
2026-09-10
Build a more informative Candida workflow by pairing Itraconazole susceptibility testing with biofilm, autophagy, and oxidative-stress readouts. Its distinct value extends to CYP3A4 drug interaction studies and carefully separated hedgehog signaling or angiogenesis inhibition assays.
-
Carrier-Free Paclitaxel Nanoparticles for TNBC
2026-09-10
A 2024 ACS Applied Nano Materials study developed PTX/GA@FA-HSA, a high-drug-loading formulation in which paclitaxel and gambogic acid coassemble into a drug-rich core coated with folate-functionalized albumin. In MDA-MB-231 cell and tumor-bearing mouse models, the formulation improved folate receptor-associated delivery while reducing the need for conventional carrier material.
-
Faropenem sodium: Research Workflows and AMR Insights
2026-09-09
Faropenem sodium combines penem-class cell-wall activity with strong anaerobic coverage, making it useful for comparative susceptibility assays and resistance-focused workflows. This guide translates its reported performance into practical experimental design, controls, and troubleshooting while emphasizing responsible interpretation of oral penem data.
-
T7 RNA Polymerase for Precise RNA Synthesis
2026-09-09
T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively produces RNA from DNA templates carrying a T7 promoter. Its defined template requirements support in vitro transcription workflows for research applications such as RNA vaccine production, antisense RNA, and RNAi studies.
-
WM-8014 KAT6A Inhibitor Workflow Guide
2026-09-08
WM-8014 combines reversible, competitive KAT6A/B inhibition with practical assays for cell-cycle arrest, senescence, and oncogenic overproliferation. This guide connects RESTRICT-seq findings to dose-response, washout, transcriptional, and in vivo-compatible workflows while emphasizing solvent, timing, and interpretation controls.
-
MiR-3180 Rewires Lipid Metabolism in HCC
2026-09-08
Hong et al. identified miR-3180 as a coordinated regulator of fatty-acid synthesis and uptake in hepatocellular carcinoma by targeting SCD1 and CD36. The study integrates patient-tissue analysis, reporter assays, cellular phenotyping, lipid measurements, and xenograft experiments, providing a mechanistic framework for interpreting lipid-metabolism biomarkers in HCC.
-
Cyanidin Chloride in Oxidative Stress Workflows
2026-09-07
Cyanidin Chloride supports a practical assay cascade spanning radical-scavenging tests, inflammatory cell models, transcriptional readouts, and epithelial barrier measurements. Its defined identity, high purity, and water, ethanol, and DMSO solubility make it useful for connecting cell-free antioxidant data with mechanistic skin-cell experiments.
-
PF-573228: Reading FAK Signals in Stiff Matrices
2026-09-07
Explore how PF-573228, a potent FAK inhibitor, can separate matrix-driven mechanotransduction from downstream cell phenotypes. This article translates the LAMB1–FAK–MEK1/2 dentinogenesis study into a rigorous assay-design framework spanning odontoblast, cancer, and endothelial models.
-
Ibrexafungerp Against Resistant Candida auris
2026-09-05
Wiederhold and colleagues showed that ibrexafungerp retained in vitro activity against 54 Candida auris isolates and improved outcomes in a neutropenic mouse model even when treatment began after infection was established. The study is notable for connecting oral glucan-synthase targeting with delayed-treatment efficacy, while benchmarking activity against fluconazole and caspofungin.